Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jpn J Clin Oncol. 2024 Jun 1;54(6):699-707. doi: 10.1093/jjco/hyae024.
This study aimed to construct a nomogram to predict radiation-induced hepatic toxicity in patients with hepatocellular carcinoma treated with intensity-modulated radiotherapy.
This study reviewed the clinical characteristics and dose-volume parameters of 196 patients with hepatocellular carcinoma. Radiation-induced hepatic toxicity was defined as progression of the Child-Pugh score caused by intensity-modulated radiotherapy. Factors relevant to radiation-induced hepatic toxicity were selected using receiver operating characteristic and univariate logistic analysis. A risk assessment model was developed, and its discrimination was validated.
Eighty-eight (44.90%) and 28 (14.29%) patients had radiation-induced hepatic toxicity ≥ 1 (Child-Pugh ≥ 1) and radiation-induced hepatic toxicity ≥ 2 (Child-Pugh ≥ 2). Pre-treatment Child-Pugh, body mass index and dose-volume parameters were correlated with radiation-induced hepatic toxicity ≥ 1 using univariate logistic analysis. V15 had the best predictive effectiveness among the dose-volume parameters in both the training (area under the curve: 0.763, 95% confidence interval: 0.683-0.842, P < 0.001) and validation cohorts (area under the curve: 0.759, 95% confidence interval: 0.635-0.883, P < 0.001). The area under the curve values of the model that was constructed by pre-treatment Child-Pugh, body mass index and V15 for radiation-induced hepatic toxicity ≥1 were 0.799 (95% confidence interval: 0.719-0.878, P < 0.001) and 0.775 (95% confidence interval: 0.657-0.894, P < 0.001) in the training and validation cohorts, respectively. Patients with a body mass index ≤ 20.425, Barcelona clinic liver cancer = C, Hepatitis B Virus-positive, Eastern Cooperative Oncology Group = 1-2 and hepatic fibrosis require lower V15 dose limits.
Risk assessment model constructed from Pre-treatment Child-Pugh, V15 and body mass index can guide individualized patient selection of toxicity minimization strategies.
本研究旨在构建一个列线图,以预测接受调强放疗的肝细胞癌患者的放射性肝毒性。
本研究回顾了 196 例肝细胞癌患者的临床特征和剂量-体积参数。放射性肝毒性定义为调强放疗引起的 Child-Pugh 评分进展。使用受试者工作特征和单因素逻辑分析选择与放射性肝毒性相关的因素。建立风险评估模型,并验证其判别能力。
88 例(44.90%)和 28 例(14.29%)患者的放射性肝毒性≥1(Child-Pugh≥1)和放射性肝毒性≥2(Child-Pugh≥2)。单因素逻辑分析显示,治疗前 Child-Pugh、体重指数和剂量-体积参数与放射性肝毒性≥1相关。在训练队列(曲线下面积:0.763,95%置信区间:0.683-0.842,P<0.001)和验证队列(曲线下面积:0.759,95%置信区间:0.635-0.883,P<0.001)中,V15 是最佳预测效能的剂量-体积参数。由治疗前 Child-Pugh、体重指数和 V15 构建的模型预测放射性肝毒性≥1 的曲线下面积值在训练队列和验证队列中分别为 0.799(95%置信区间:0.719-0.878,P<0.001)和 0.775(95%置信区间:0.657-0.894,P<0.001)。体重指数≤20.425、巴塞罗那临床肝癌分级 C、乙型肝炎病毒阳性、东部肿瘤协作组体力状况 1-2 和肝纤维化的患者需要更低的 V15 剂量限制。
由治疗前 Child-Pugh、V15 和体重指数构建的风险评估模型可指导最小化毒性策略的个体化患者选择。